Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial

Clinical Immunology

Volumn 160, Issue 2, 2015, Pages 349-357

  Esmaeilzadeh, Hossein ^a,b   Nabavi, Mohammad ^a   Aryan, Zahra ^c   Arshi, Saba ^a   Bemanian, Mohammad Hassan ^a   Fallahpour, Morteza ^a   Mortazavi, Negar ^d  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Aspirin intolerant asthma; Desensitization; Interferon gamma; Interleukin 10; Quality of life

Indexed keywords

ACETYLSALICYLIC ACID; GAMMA INTERFERON; INTERLEUKIN 10; KETOROLAC; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; IL10 PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; BLOOD LEVEL; CHRONIC RHINOSINUSITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL HEMORRHAGE; HUMAN; MALE; NOSE POLYP; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; ASTHMA, ASPIRIN-INDUCED; IMMUNOLOGY; NASAL POLYPS; PROCEDURES; RHINITIS; SINUSITIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ASTHMA, ASPIRIN-INDUCED; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; MALE; NASAL POLYPS; RHINITIS; SINUSITIS; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942520043     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.05.012     Document Type: Article

References (36)

1. Bousquet J., Bachert C., Canonica G.W., Casale T.B., Cruz A.A., Lockey R.J., ... Its impact on asthma study G, unmet needs in severe chronic upper airway disease (SCUAD). J. Allergy Clin. Immunol. 2009, 124:428-433.
2. Aryan Z., Compalati E., Canonica G.W., Rezaei N. Allergen-specific immunotherapy in asthmatic children: from the basis to clinical applications. Expert Rev. Vaccines 2013, 12:639-659.
3. Jenneck C., Juergens U., Buecheler M., Novak N. Pathogenesis, diagnosis, and treatment of aspirin intolerance. Ann. Allergy Asthma Immunol. 2007, 99:13-21.
4. Esmaeilzadeh H., Nabavi M., Amirzargar A.A., Aryan Z., Arshi S., Bemanian M.H., ..., Rezaei N. HLA-DRB and HLA-DQ genetic variability in patients with aspirin-exacerbated respiratory disease. Am. J. Rhinol. Allergy 2015, 29:63-69.
5. Lee R.U., White A.A. Ding D, Dursun AB, Woessner KM, Simon RA, Stevenson DD, Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann. Allergy Asthma Immunol. 2010, 105:130-135.
6. Lee J.Y., Simon R.A., Stevenson D.D. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. 2007, 119:157-164.
7. Rozsasi A., Polzehl D., Deutschle T., Smith E., Wiesmiller K., Riechelmann H., Keck T. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300mg aspirin daily. Allergy 2008, 63:1228-1234.
8. Choi G.S., Kim J.H., Shin Y.S., Ye Y.M., Kim S.H., Park H.S. Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD. Clin. Exp. Allergy 2013, 43:730-740.
9. Corrigan C., Mallett K., Ying S., Roberts D., Parikh A., Scadding G., Lee T. Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J. Allergy Clin. Immunol. 2005, 115:316-322.
10. Steinke J.W., Liu L., Huyett P., Negri J., Payne S.C., Borish L. Prominent role of IFN-gamma in patients with aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. 2013, 132:e1-e3. (856-65).
11. Akbari O., DeKruyff R.H., Umetsu D.T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. 2001, 2:725-731.
12. Aksu K., Kurt E., Alatas O., Gulbas Z. Effect of aspirin desensitization on T-cell cytokines and plasma lipoxins in aspirin-exacerbated respiratory disease. Allergy Asthma Proc. 2014, 35:148-155.
13. Aktas A., Kurt E., Gulbas Z. Cytokine expression before and after aspirin desensitization therapy in aspirin-exacerbated respiratory disease. Inflammation 2013, 36:1553-1559.
14. Kim S.H., Yang E.M., Lee H.N., Cho B.Y., Ye Y.M., Park H.S. Combined effect of IL-10 and TGF-beta1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis. Allergy 2009, 64:1221-1225.
15. Katial R.K., Strand M., Prasertsuntarasai T., Leung R., Zheng W., Alam R. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J. Allergy Clin. Immunol. 2010, 126:738-744.
16. White A.A., Stevenson D.D. Does suppression of IL-4 synthesis by aspirin explain the therapeutic benefit of aspirin desensitization treatment?. J. Allergy Clin. Immunol. 2010, 126:745-746.
17. Fokkens W.J., Lund V.J., Mullol J., Bachert C., Alobid I., Baroody F., ..., Wormald P.J. European Position Paper on Rhinosinusitis and Nasal Polyps. Rhinol. Suppl. 2012, 1-298. (3 p preceding table of contents).
18. Bateman E.D., Hurd S.S., Barnes P.J., Bousquet J., Drazen J.M., FitzGerald M., ..., Zar H.J. Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J. 2008, 31:143-178.
19. Nabavi M., Esmaeilzadeh H., Arshi S., Bemanian M.H., Fallahpour M., Bahrami A., ..., Rezaei N. Aspirin hypersensitivity in patients with chronic rhinosinusitis and nasal polyposis: frequency and contributing factors. Am. J. Rhinol. Allergy 2014, 28:239-243.
20. Macy E., Bernstein J.A., Castells M.C., Gawchik S.M., Lee T.H., Settipane R.A., Aspirin Desensitization Joint Task F, Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann. Allergy Asthma Immunol. 2007, 98:172-174.
21. Hopkins C., Gillett S., Slack R., Lund V.J., Browne J.P. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin. Otolaryngol. 2009, 34:447-454.
22. Lund V.J., Mackay I.S. Staging in rhinosinusitus. Rhinology 1993, 31:183-184.
23. Comert S., Celebioglu E., Yucel T., Erdogan T., Karakaya G., Onerci M., Kalyoncu A.F. Aspirin 300mg/day is effective for treating aspirin-exacerbated respiratory disease. Allergy 2013, 68:1443-1451.
24. Berges-Gimeno M.P., Simon R.A., Stevenson D.D. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann. Allergy Asthma Immunol. 2003, 90:338-341.
25. Fruth K., Pogorzelski B., Schmidtmann I., Springer J., Fennan N., Fraessdorf N., ..., Mann W.J. Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy 2013, 68:659-665.
26. Stevenson D.D., Pleskow W.W., Simon R.A., Mathison D.A., Lumry W.R., Schatz M., Zeiger R.S. Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J. Allergy Clin. Immunol. 1984, 73:500-507.
27. Swierczynska-Krepa M., Sanak M., Bochenek G., Strek P., Cmiel A., Gielicz A., ..., Nizankowska-Mogilnicka E. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: A double-blind study. J. Allergy Clin. Immunol. October 2014, 134(4):883-890.
28. Cowburn A.S., Sladek K., Soja J., Adamek L., Nizankowska E., Szczeklik A., ..., Sampson A.P. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J. Clin. Invest. 1998, 101:834-846.
29. Togo K., Suzuki Y., Yoshimaru T., Inoue T., Terui T., Ochiai T., Ra C. Aspirin and salicylates modulate IgE-mediated leukotriene secretion in mast cells through a dihydropyridine receptor-mediated Ca(2+) influx. Clin. Immunol. 2009, 131:145-156.
30. Le Y., Wetzel M.A., Shen W., Gong W., Rogers T.J., Henderson E.E., Wang J.M. Desensitization of chemokine receptor CCR5 in dendritic cells at the early stage of differentiation by activation of formyl peptide receptors. Clin. Immunol. 2001, 99:365-372.
31. Maguire P., Nicodemus C., Robinson D., Aaronson D., Umetsu D.T. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin. Immunol. 1999, 93:222-231.
32. Kowalski M.L., Asero R., Bavbek S., Blanca M., Blanca-Lopez N., Bochenek G., ..., Makowska J. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 2013, 68:1219-1232.
33. Sousa A.R., Parikh A., Scadding G., Corrigan C.J., Lee T.H. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N. Engl. J. Med. 2002, 347:1493-1499.
34. Nabavi M., Arshi S., Bahrami A., Aryan Z., Bemanian M.H., Esmaeilzadeh H., ..., Rezaei N. Increased level of interleukin-13, but not interleukin-4 and interferon-gamma in chronic rhinosinusitis with nasal polyps. Allergol. Immunopathol. (Madr.) 2014, 42:465-471.
35. Shome G.P., Tarbox J., Shearer M., Kennedy R. Cytokine expression in peripheral blood lymphocytes before and after aspirin desensitization in aspirin-exacerbated respiratory disease. Allergy Asthma Proc. 2007, 28:706-710.
36. Grimbaldeston M.A., Nakae S, Kalesnikoff J, Tsai M, Galli SJ Mast cell-derived interleukin-10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat. Immunol. 2007, 8:1095-1104.